Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Mylan and Biocon today became the first drugmakers to win an FDA approval of a biosimilar of Roche's blockbuster cancer drug Herceptin.
Bluebird Bio bought a manufacturing site in Durham, North Carolina, as it prepares to bring gene therapies to market over the next four years.
Seqirus will invest £40 million into its U.K. site, adding about 100 jobs so it can shorten production time for its Fluad influenza vaccine.
Merck KGaA and South Korea’s Samsung BioLogics are deepening a collaboration even as Samsung reported an operating profit for the first time.
The Pakistani ambassador in Azerbaijan said pharmaceutical companies from his country are looking to develop joint ventures in drug production there.
Zydus Cadila, an Indian injectables maker, said it reached a deal with Russia’s Pharm Aid to manufacture its varicella vaccine for the Russian Federation.
Valeant says the situation is looking up at that Bausch + Lomb plant that has twice been responsible for Valeant receiving a CRL for a new eye drug.
Soligenix just got another $2.5 million awarded from an NIAID contract to support manufacturing of a heat-stable ricin vaccine for future studies.
Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices.
Particle Sciences will have commercial manufacturing capabilities operating at its Pennsylvania facility by the end of the year and will add 30 jobs.